Table of Contents
Understanding Afrezza: An Innovative Approach to Diabetes Management
Afrezza is the only ultra rapid-acting inhaled insulin that starts lowering blood sugars in approximately 12 minutes for adults living with type 1 or type 2 diabetes. Unlike traditional injectable insulins, this medication is delivered through inhalation, offering a needle-free alternative for mealtime insulin therapy. Once inhaled, Afrezza passes quickly through your lungs and enters your bloodstream in less than 1 minute, and the ultra rapid-acting insulin allows Afrezza to start controlling blood sugars in about 12 minutes.
While Afrezza provides significant convenience and rapid glucose control, it’s essential for patients and healthcare providers to understand its potential side effects and how to minimize associated risks. This comprehensive guide explores the common and serious side effects of Afrezza, contraindications, monitoring requirements, and practical strategies for safe use.
Common Side Effects of Afrezza
Most patients who use Afrezza experience mild side effects that often diminish as the body adjusts to the medication. Understanding these common reactions can help you distinguish between normal adjustment periods and situations requiring medical attention.
Cough and Throat Irritation
Cough is the most distinctive Afrezza side effect, with a dry, non-productive cough typically occurring within minutes of inhalation. In clinical trials, cough affected about 25-30% of patients, and it usually decreases over time as your body adjusts. Since Afrezza is an inhaled powder, you may experience a cough when you start Afrezza.
This cough is generally not a cause for concern and represents the body’s natural response to inhaling a powdered medication. However, if the cough persists beyond the initial adjustment period or becomes severe, it’s important to consult your healthcare provider. Mild throat discomfort is common in the first few weeks, and drinking water after inhalation can help.
Hypoglycemia (Low Blood Sugar)
The most common side effects of Afrezza include low blood sugar (hypoglycemia), cough, and sore throat. Hypoglycemia is a risk with all insulin products, including Afrezza. Hypoglycemia is the most common adverse reaction associated with insulins, including Afrezza, and severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
Symptoms of low blood sugar include anxiety, behavior change similar to being drunk, blurred vision, cold sweats, confusion, depression, difficulty in thinking, dizziness or lightheadedness, drowsiness, excessive hunger, fast heartbeat, headache, irritability or abnormal behavior, nervousness, nightmares, restless sleep, shakiness, slurred speech, and tingling in the hands, feet, lips, or tongue.
The rapid action profile of Afrezza means that hypoglycemia can occur quickly after administration. Hypoglycemia can impair concentration ability and reaction time, which may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation, and Afrezza has a distinct time action profile which impacts the timing of hypoglycemia.
Upper Respiratory Symptoms
Beyond cough and throat irritation, some patients experience additional upper respiratory symptoms including nasal congestion, sore throat, and hoarseness. Throat pain or irritation is common (1% to 10%). These symptoms are typically mild and transient, resolving within the first few weeks of treatment as the respiratory system adapts to the inhaled medication.
Patients should maintain good hydration and consider using the inhaler in a well-ventilated area to minimize discomfort. If these symptoms persist or worsen, medical evaluation is warranted to rule out more serious respiratory complications.
Headache
Headaches are another commonly reported side effect during the initial weeks of Afrezza therapy. These headaches may be related to changes in blood glucose levels as the body adjusts to the new insulin regimen. Maintaining consistent blood sugar monitoring and ensuring proper dosing can help minimize this side effect.
Serious Side Effects and Risks
While most side effects of Afrezza are mild and manageable, there are serious risks that require immediate medical attention. Understanding these potential complications is crucial for safe use of this medication.
Acute Bronchospasm: The Most Serious Risk
The most serious risk is acute bronchospasm — sudden tightening of the airways that can cause severe difficulty breathing. This is the subject of Afrezza’s FDA boxed warning and is the reason it’s contraindicated in patients with chronic lung conditions. Afrezza can cause sudden lung problems (bronchospasms), and in a study, some Afrezza-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems.
Acute bronchospasm has been observed in Afrezza-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD), and Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD. Acute bronchospasm has been observed following Afrezza dosing in patients with asthma and patients with COPD. In a study of patients with asthma, bronchoconstriction and wheezing following Afrezza dosing was reported in 29% (5 out of 17) and 0% (0 out of 13) of patients with and without a diagnosis of asthma, respectively.
Symptoms of bronchospasm include sudden difficulty breathing, wheezing, chest tightness, and severe coughing. If you experience any of these symptoms after using Afrezza, seek emergency medical attention immediately.
Decline in Lung Function
In clinical trials of up to 2 years duration, a 15% or greater reduction in forced expiratory volume (FEV1) occurred in 6% of patients treated with inhaled insulin compared with a 3% decline in patients receiving comparator anti-diabetes treatment. Patients with chronic lung disease were not included in these studies. The FEV1 decline occurred during the first 3 months and persisted; it did not appear to worsen with increased duration of use.
Afrezza can cause a small decline in lung function (FEV1) over time, which is why the FDA requires spirometry testing before starting, at 6 months, and annually. This decline in pulmonary function is one of the most significant long-term concerns with Afrezza use and necessitates regular monitoring throughout treatment.
Lung Cancer Concerns
In clinical trials, two cases of lung cancer (2 cases in 2,750 patient-years of exposure) were observed in participants exposed to Afrezza while no cases of lung cancer were observed in comparators (0 cases in 2,169 patient-years of exposure). In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell) occurred in non-smokers exposed to Afrezza and were reported by investigators after clinical trial completion. These data are insufficient to determine whether Afrezza has an effect on lung or respiratory tract tumors.
While the data remains inconclusive, the FDA has required post-marketing studies to evaluate the potential risk of pulmonary malignancy with long-term Afrezza use. Patients with a history of lung cancer or significant smoking history should discuss these concerns thoroughly with their healthcare provider before starting Afrezza.
Severe Hypoglycemia
Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving). Someone should call for emergency help immediately if severe symptoms such as convulsions (seizures) or unconsciousness occur. Have a glucagon kit available, along with a syringe and needle, and know how to use it.
Hypoglycemia can happen suddenly and symptoms may differ across individuals and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using certain medications, or in patients who experience recurrent hypoglycemia.
Allergic Reactions
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Afrezza. Signs of a severe allergic reaction include rash, itching, swelling (especially of the face, tongue, or throat), severe dizziness, and difficulty breathing. Any signs of an allergic reaction require immediate medical attention.
Diabetic Ketoacidosis
New concerns were brought forward after Afrezza’s approval, prompting the FDA to require a risk evaluation and mitigation strategy and a “black-box” warning informing patients of an increased risk of acute bronchospasm in those with chronic lung disease. Diabetic ketoacidosis (DKA) was also found to be more common in patients in the Afrezza cohort. DKA is a serious complication that occurs when the body doesn’t have enough insulin and begins breaking down fat for energy, producing ketones that can make the blood acidic.
Symptoms of DKA include nausea, vomiting, stomach pain, excessive thirst, dry mouth, fruity-smelling breath, difficulty breathing, and confusion. This is a medical emergency requiring immediate treatment.
Hypokalemia (Low Potassium)
All insulin products, including Afrezza, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in Afrezza-treated patients at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations and patients receiving intravenously administered insulin).
Who Should Not Use Afrezza: Contraindications
Certain individuals should not use Afrezza due to increased risk of serious complications. Understanding these contraindications is essential for patient safety.
Chronic Lung Disease
Do not use Afrezza if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). People with asthma and chronic obstructive pulmonary disease (COPD) who used Afrezza have had sudden bronchospasm. As a result, having a long-term lung condition such as asthma or COPD is a contraindication to taking Afrezza.
This contraindication is absolute due to the significant risk of acute bronchospasm in patients with underlying lung disease. Even well-controlled asthma or mild COPD represents an unacceptable risk for Afrezza use.
Smoking and Recent Smoking Cessation
It is not known if Afrezza is safe and effective for use in people who smoke. Afrezza is not for use in people who smoke or have recently stopped smoking (less than 6 months). Afrezza is not recommended for current smokers or people who recently quit smoking. Smoking can change how insulin is absorbed through the lungs and may increase the risk of respiratory side effects.
Smoking affects lung function and insulin absorption, making Afrezza both less effective and potentially more dangerous in smokers. Patients must have been smoke-free for at least six months before Afrezza can be considered as a treatment option.
Hypoglycemia Episodes
Afrezza is contraindicated during episodes of low blood sugar (hypoglycemia). Taking additional insulin when blood sugar is already low can lead to severe and potentially life-threatening hypoglycemia.
Diabetic Ketoacidosis
Afrezza is not for use to treat diabetic ketoacidosis. DKA requires immediate medical treatment with intravenous insulin and fluids. Afrezza’s rapid but short duration of action makes it unsuitable for managing this acute complication.
Allergy to Insulin or Afrezza Components
Afrezza is contraindicated in patients who are allergic to regular human insulin or any of the ingredients in Afrezza. Patients with known hypersensitivity reactions to insulin products should not use Afrezza.
How to Minimize Risks When Using Afrezza
While Afrezza carries certain risks, following proper precautions and monitoring protocols can significantly reduce the likelihood of adverse effects. Here are comprehensive strategies for safe Afrezza use.
Mandatory Lung Function Testing
Assess pulmonary function with spirometry at baseline, after the first 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In patients who have a decline of ≥20% in FEV1 from baseline, consider discontinuing Afrezza. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue Afrezza.
Before starting Afrezza, your healthcare provider will give you a breathing test to check how your lungs are working. This baseline spirometry is essential for establishing your lung function before treatment and provides a reference point for future comparisons.
Regular spirometry testing allows for early detection of declining lung function, enabling timely intervention before serious complications develop. Patients should never skip scheduled lung function tests, as these are critical safety monitoring tools.
Proper Dosing and Administration
Using Afrezza exactly as prescribed is crucial for both efficacy and safety. Use this medicine only as directed by your doctor. Do not use more of it and do not use it more often than your doctor ordered. Also, do not stop using this medicine without telling your doctor. To do so may increase the chance of side effects.
Afrezza is a mealtime insulin. It should be taken at the beginning of a meal. Proper timing is essential to match insulin action with carbohydrate absorption and prevent both hyperglycemia and hypoglycemia.
Patients should receive thorough training on proper inhaler technique. If you do not understand the directions or you are not sure how to use the inhaler, ask your doctor to show you what to do. Also, ask your doctor to check regularly how you use the inhaler to make sure you are using it properly. Incorrect technique can result in inadequate insulin delivery and poor glucose control.
Comprehensive Blood Glucose Monitoring
Glucose monitoring is essential for patients receiving insulin therapy. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made under close medical supervision and the frequency of blood glucose monitoring should be increased.
Patients should monitor blood glucose levels before meals, two hours after meals, at bedtime, and whenever hypoglycemia is suspected. Continuous glucose monitoring (CGM) systems can provide real-time glucose data and alerts for high and low blood sugar, offering an additional layer of safety.
Keep detailed records of blood glucose readings, insulin doses, meals, and physical activity. This information helps healthcare providers make informed adjustments to your treatment plan and identify patterns that may increase risk of complications.
Thorough Medical History Disclosure
Before initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients. Be completely honest with your healthcare provider about your medical history, including:
- Any history of lung disease, even if mild or well-controlled
- Current or past smoking history
- Allergies to medications, especially insulin products
- History of severe hypoglycemia or hypoglycemia unawareness
- Kidney or liver disease
- Heart disease or heart failure
- All medications and supplements you’re currently taking
- Pregnancy or plans to become pregnant
This information allows your healthcare provider to assess whether Afrezza is appropriate for you and to implement necessary precautions.
Recognizing and Responding to Warning Signs
Knowing when to seek medical attention is crucial for preventing serious complications. Contact your healthcare provider immediately if you experience:
- Persistent or worsening cough that doesn’t improve after the first few weeks
- Any difficulty breathing, wheezing, or chest tightness
- Frequent episodes of hypoglycemia
- Signs of hyperglycemia (excessive thirst, frequent urination, blurred vision)
- Symptoms of DKA (nausea, vomiting, fruity breath, confusion)
- Any signs of allergic reaction
- Unexplained weight loss or respiratory symptoms
For severe symptoms such as severe difficulty breathing, loss of consciousness, seizures, or signs of anaphylaxis, call emergency services immediately rather than waiting for a scheduled appointment.
Medication Interactions and Adjustments
Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents. Many medications can affect blood glucose levels and insulin requirements, including:
- Other diabetes medications
- Beta-blockers
- Corticosteroids
- Atypical antipsychotics
- Certain antibiotics
- Alcohol
Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited). Always inform all healthcare providers about your Afrezza use and discuss potential interactions before starting new medications.
Proper Storage and Handling
Correct storage of Afrezza is essential for maintaining its effectiveness and safety. Keep unopened foil packages in the refrigerator until their expiration date. After opening the package, store unopened blister cards and strips of cartridges in the refrigerator for up to 1 month. You can also keep them at room temperature for up to 10 days. Opened strips can stay at room temperature, you have to use them within 3 days. Don’t put anything back in the refrigerator after they reach room temperature.
Throw away the inhaler after 15 days and get a new one. Using an inhaler beyond its recommended lifespan can compromise drug delivery and effectiveness.
Emergency Preparedness
All insulin users should be prepared for hypoglycemia emergencies. If symptoms of low blood sugar occur, eat glucose tablets or gel to relieve the symptoms. Also, check your blood for low blood sugar. Get to a doctor or a hospital right away if the symptoms do not improve.
Keep the following emergency supplies readily available:
- Fast-acting glucose tablets or gel
- Glucagon emergency kit with clear instructions
- Medical identification bracelet or card indicating diabetes and insulin use
- Emergency contact information
- List of all medications and dosages
Ensure family members, roommates, or close friends know how to recognize hypoglycemia symptoms and how to administer glucagon in an emergency.
Lifestyle Considerations
Certain lifestyle factors can affect Afrezza’s safety and effectiveness:
Exercise: Physical activity increases insulin sensitivity and can lower blood glucose levels. Adjust insulin doses or carbohydrate intake before, during, or after exercise as recommended by your healthcare provider. Monitor blood glucose more frequently when changing exercise routines.
Alcohol: Alcohol can affect blood glucose levels unpredictably, potentially causing both hypoglycemia and hyperglycemia. If you choose to drink alcohol, do so in moderation, never on an empty stomach, and monitor blood glucose closely.
Illness: Sickness, infections, and stress can significantly affect blood glucose levels and insulin requirements. During illness, monitor blood glucose more frequently, stay hydrated, and maintain contact with your healthcare provider. In patients at risk for DKA, such as those with an acute illness or infection, increase the frequency of glucose monitoring and consider delivery of insulin using an alternate route of administration if indicated.
Respiratory Infections: Upper respiratory infections deserve special attention for Afrezza users. While studies have shown that symptomatic upper respiratory tract infections can affect insulin absorption and action, patients should continue monitoring and report any significant changes in glucose control or respiratory symptoms to their healthcare provider.
Special Populations and Considerations
Type 1 Diabetes Patients
Afrezza is not for use in place of long-acting insulin. Afrezza must be used with long-acting insulin. Patients with type 1 diabetes require basal insulin coverage in addition to mealtime insulin. Afrezza should never be used as the sole insulin therapy in type 1 diabetes, as this can lead to diabetic ketoacidosis.
Pregnancy and Breastfeeding
Afrezza should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative insulin options with their healthcare provider. Tight glucose control is essential during pregnancy, but the safety profile of Afrezza in these populations has not been fully established.
Pediatric Patients
It is not known if Afrezza is safe and effective in children under 18 years of age. Appropriate studies have not been performed on the relationship of age to the effects of insulin human inhaled in the pediatric population. Safety and efficacy have not been established. Afrezza is currently approved only for adult patients.
Elderly Patients
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of insulin human inhaled in the elderly. However, elderly patients may be at increased risk for hypoglycemia due to decreased awareness of symptoms, irregular eating patterns, or concurrent medications. More frequent monitoring may be appropriate for older adults using Afrezza.
Patients with Heart Failure
Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including Afrezza, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist should be considered.
Converting from Other Insulin Products
When switching from another insulin to inhaled insulin, a different insulin dosage may be needed and increased frequency of blood glucose monitoring and monitoring for signs and symptoms of hypoglycemia may be needed. The conversion from injectable insulin to Afrezza is not a simple one-to-one ratio.
Because Afrezza is inhaled, and is in powdered form, one unit of Afrezza may work differently than one unit of injectable, liquid insulin. Based on clinical trials, it may take 1.5x the amount of Afrezza to achieve the same blood sugar control as injected insulin. This difference in potency requires careful dose titration under medical supervision.
During the conversion period, patients should monitor blood glucose more frequently and maintain close communication with their healthcare provider. Dose adjustments may be necessary based on individual response and glucose patterns.
Long-Term Monitoring and Follow-Up
Successful long-term use of Afrezza requires ongoing monitoring and regular follow-up with your healthcare team. Establish a comprehensive monitoring schedule that includes:
- Spirometry testing at baseline, 6 months, and annually thereafter
- Hemoglobin A1C testing every 3 months
- Regular review of blood glucose logs and patterns
- Assessment of hypoglycemia frequency and severity
- Evaluation of injection site reactions or respiratory symptoms
- Review of medication adherence and proper inhaler technique
- Discussion of any new symptoms or concerns
Your healthcare provider may adjust the frequency of visits and testing based on your individual needs, glucose control, and any emerging concerns.
When to Consider Alternative Treatments
While Afrezza offers unique benefits, it may not be the best choice for everyone. Consider discussing alternative insulin options with your healthcare provider if:
- You develop persistent respiratory symptoms that don’t improve
- Spirometry shows a significant decline in lung function
- You experience frequent or severe hypoglycemia
- Glucose control remains inadequate despite dose adjustments
- You develop new respiratory conditions
- The cost or insurance coverage becomes prohibitive
- You find the inhaler technique difficult to master
There are many effective insulin options available, including rapid-acting insulin analogs (insulin aspart, insulin lispro, insulin glulisine), regular human insulin, and various insulin delivery systems. Your healthcare provider can help you find the most appropriate treatment for your individual circumstances.
The Importance of Patient Education
Comprehensive patient education is fundamental to safe Afrezza use. Before starting treatment, ensure you understand:
- How to properly use the Afrezza inhaler
- When to take your doses in relation to meals
- How to recognize and treat hypoglycemia
- Warning signs of serious side effects
- Proper storage and handling of cartridges and inhalers
- When to contact your healthcare provider
- How to monitor and record blood glucose levels
- The importance of regular lung function testing
Don’t hesitate to ask questions or request additional training if anything is unclear. Many healthcare providers offer diabetes education programs, and pharmaceutical companies often provide instructional materials and support programs for patients using their products.
Support Resources and Additional Information
Several resources are available to support patients using Afrezza:
Manufacturer Support Programs: MannKind Corporation offers patient assistance programs that may help with medication costs and provide educational materials. Visit the official Afrezza website or contact their patient support line for information about available resources.
Diabetes Education: Certified diabetes educators can provide personalized instruction on insulin management, blood glucose monitoring, and lifestyle modifications. Ask your healthcare provider for a referral to a diabetes education program.
Professional Organizations: Organizations such as the American Diabetes Association and the Endocrine Society offer evidence-based information about diabetes management and treatment options.
FDA Resources: The FDA’s MedWatch program allows patients to report side effects and access important safety information about medications.
Consult Your Healthcare Provider
The decision to use Afrezza should be made collaboratively between you and your healthcare provider, taking into account your individual medical history, lifestyle, preferences, and treatment goals. Always discuss potential side effects and risks with your doctor before starting Afrezza.
Regular check-ups are vital to ensure safe and effective treatment. Your healthcare provider will monitor your glucose control, lung function, and overall health to optimize your diabetes management while minimizing risks. If you experience any adverse reactions, seek medical advice immediately rather than waiting for your next scheduled appointment.
Remember that diabetes management is a partnership between you and your healthcare team. Open communication, adherence to monitoring protocols, and prompt reporting of concerns are essential components of successful treatment with Afrezza or any insulin therapy.
Conclusion
Afrezza represents an innovative approach to mealtime insulin delivery, offering rapid action and needle-free administration for adults with diabetes. While it provides significant benefits for many patients, understanding its potential side effects and implementing appropriate risk-minimization strategies is essential for safe use.
Common side effects such as cough, throat irritation, and hypoglycemia are generally manageable with proper education and monitoring. However, serious risks including acute bronchospasm and declining lung function require vigilant surveillance through regular spirometry testing and prompt attention to respiratory symptoms.
By following prescribed dosing guidelines, maintaining comprehensive blood glucose monitoring, attending all scheduled follow-up appointments, and promptly reporting any concerning symptoms, patients can maximize the benefits of Afrezza while minimizing potential risks. The key to successful Afrezza therapy lies in informed decision-making, proper technique, consistent monitoring, and ongoing communication with your healthcare team.
If you’re considering Afrezza or currently using this medication, work closely with your healthcare provider to ensure it remains the most appropriate treatment option for your individual needs. With proper precautions and monitoring, many patients successfully use Afrezza as part of their comprehensive diabetes management plan.